Correlation Between Zenas BioPharma, and Encision

Can any of the company-specific risk be diversified away by investing in both Zenas BioPharma, and Encision at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Zenas BioPharma, and Encision into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Zenas BioPharma, Common and Encision, you can compare the effects of market volatilities on Zenas BioPharma, and Encision and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Zenas BioPharma, with a short position of Encision. Check out your portfolio center. Please also check ongoing floating volatility patterns of Zenas BioPharma, and Encision.

Diversification Opportunities for Zenas BioPharma, and Encision

-0.36

Correlation Coefficient

Zenas BioPharma,  Encision

Very good diversification

The 3 months correlation between Zenas and Encision is -0.36. Overlapping area represents the amount of risk that can be diversified away by holding Zenas BioPharma, Common and Encision in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Encision and Zenas BioPharma, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Zenas BioPharma, Common are associated (or correlated) with Encision. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Encision has no effect on the direction of Zenas BioPharma, i.e., Zenas BioPharma, and Encision go up and down completely randomly.

Pair Corralation between Zenas BioPharma, and Encision

Given the investment horizon of 90 days Zenas BioPharma, Common is expected to under-perform the Encision. In addition to that, Zenas BioPharma, is 1.76 times more volatile than Encision. It trades about -0.12 of its total potential returns per unit of risk. Encision is currently generating about -0.01 per unit of volatility. If you would invest  50.00  in Encision on September 29, 2024 and sell it today you would lose (6.00) from holding Encision or give up 12.0% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	54.81%
Values	Daily Returns

Zenas BioPharma, Common  vs.  Encision

Zenas BioPharma, Common

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Zenas BioPharma, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Etf's forward indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the ETF investors.

Encision

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Encision has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong forward indicators, Encision is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Zenas BioPharma, and Encision

The main advantage of trading using opposite Zenas BioPharma, and Encision positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Zenas BioPharma, position performs unexpectedly, Encision can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Encision will offset losses from the drop in Encision's long position.

The idea behind Zenas BioPharma, Common and Encision pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.